

Acasti Pharma Inc

11:22 11 Mar 2020

Acasti Pharma logs three patents in US, Mexico and Japan for flagship drug CaPre

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has been awarded a notice of allowance for its fourth patent from the US Patent and Trademark office plus a second notice of allowance for its third patent in Mexico.

These new patents strengthen the intellectual property case for the Canadian biopharma's flagship drug candidate CaPre, an omega-3 phospholipid that treats severe hypertriglyceridemia, which occurs when triglyceride levels rise.

READ: Acasti Pharma updates on TRILOGY 1 and TRILOGY 2 Phase 3 trials of lead heart drug CaPre

Indeed, the new patents broaden Acasti's claims for its drug to include any composition containing the two long-chain omega-3 fatty acids - EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), where at least half of the composition consists of phospholipids, a key class of lipids.

In other news, Acasti is also on the receiving end of a favorable decision by the Japan Patent Office, securing its second patent for CaPre in Japan.

"The United States and Mexico represent important markets for Acasti, given the high prevalence of hypertriglyceridemia and the need for an effective, safe and well-absorbing omega-3 therapeutic for the treatment of cardiovascular-related diseases," said Dr. Pierre Lemieux, Acasti's chief operating officer and chief scientific officer in a statement.

"These patents strengthen the company's strategic position in these important markets, which could support valuable commercial opportunities in the future. In addition, Acasti's success in upholding its patent in Japan is another confirmation of the strength of our claims and IP portfolio," he added.

Acasti CEO Jan D'Alvise expects to submit a meeting request for CaPre with the Food and Drug Administration by the close of March. "We look forward to reporting further developments, including an update on a meeting date as soon as it has been set," D'Alvise said.

Shares added 11.5% in Toronto to C\$0.58 each.

---Updates for share price---

Price: 0.72

Market Cap: \$66.59 m

1 Year Share Price Graph



Share Information

Code: ACST

Listing: TSX-V

52 week	High	Low
	4.05	0.35

Sector: Pharma & Biotech

Website: www.acastipharma.com

Company Synopsis:

Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).